Skip to main content

Table 1 Basic characteristics of patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTL) in distinct ABO blood type groups

From: Prognostic role of ABO blood type in patients with extranodal natural killer/T cell lymphoma, nasal type: a triple-center study

Characteristic

Total (cases)

Blood four-type group [cases (%)]

P

Blood two-type group [cases (%)]

P

O

A

B

AB

O

Non-O

Total

697

255

195

188

59

 

255

442

 

Age (years)

     

0.313

  

0.722

 ≤60

597

220 (86.3)

162 (83.1)

167 (88.8)

48 (81.4)

 

220 (86.3)

377 (85.3)

 

 >60

100

35 (13.7)

33 (16.9)

21 (11.2)

11 (18.6)

 

35 (13.7)

65 (14.7)

 

Gender

     

0.854

  

0.730

 Male

492

178 (69.8)

137 (70.3)

137 (72.9)

40 (67.8)

 

178 (69.8)

314 (71.0)

 

 Female

205

77 (30.2)

58 (29.7)

51 (27.1)

19 (32.2)

 

77 (30.2)

128 (29.0)

 

ECOG PS

     

0.960

  

0.911

 0–1

680

249 (97.6)

190 (97.4)

184 (97.9)

57 (96.6)

 

249 (97.6)

431 (97.5)

 

 ≥2

17

6 (2.4)

5 (2.6)

4 (2.1)

2 (3.4)

 

6 (2.4)

11 (2.5)

 

B symptoms

     

0.295

  

0.133

 Yes

324

109 (42.7)

101 (51.8)

86 (45.7)

28 (47.5)

 

109 (42.7)

215 (48.6)

 

 No

373

146 (57.3)

94 (48.2)

102 (54.3)

31 (52.5)

 

146 (57.3)

227 (51.4)

 

LDH (U/L)

     

0.596

  

0.602

 >245

194

68 (26.7)

53 (27.2)

59 (31.4)

14 (23.7)

 

68 (26.7)

126 (28.5)

 

 ≤245

503

187 (73.3)

142 (72.8)

129 (68.6)

45 (76.3)

 

187 (73.3)

316 (71.5)

 

Tumor size (cm)

     

0.399

  

0.953

 ≥5

65

24 (9.4)

21 (10.8)

18 (9.6)

2 (3.4)

 

24 (9.4)

41 (9.3)

 

 <5

632

231 (90.6)

174 (89.2)

170 (90.4)

57 (96.6)

 

231 (90.6)

401 (90.7)

 

Extranodal sites ≥2

     

0.685

  

0.966

 Yes

77

28 (11.0)

22 (11.3)

18 (9.6)

9 (15.3)

 

28 (11.0)

49 (11.1)

 

 No

620

227 (89.0)

173 (88.7)

170 (90.4)

50 (84.7)

 

227 (89.0)

393 (88.9)

 

Regional LN involvement

     

0.605

  

0.239

 Yes

171

69 (27.1)

42 (21.5)

46 (24.5)

14 (23.7)

 

69 (27.1)

102 (23.1)

 

 No

526

186 (72.9)

153 (78.5)

142 (75.5)

45 (76.3)

 

186 (72.9)

340 (76.9)

 

EBV-DNA (copies/mL)a

     

0.435

  

0.829

 <1530

85

31 (50.8)

20 (46.5)

22 (44.9)

12 (66.7)

 

31 (50.8)

54 (49.1)

 

 ≥1530

86

30 (49.2)

23 (53.5)

27 (55.1)

6 (33.3)

 

30 (49.2)

56 (50.9)

 

CRP (mg/L)b

     

0.197

  

0.038

 ≤10

128

55 (61.1)

26 (50.0)

36 (46.3)

11 (42.1)

 

55 (61.1)

73 (47.1)

 

 >10

100

35 (38.9)

26 (50.0)

31 (53.7)

8 (57.9)

 

35 (38.9)

65 (52.9)

 

Ann Arbor stage

     

0.749

  

0.894

 I/II

619

227 (89.0)

173 (88.7)

169 (89.9)

50 (84.7)

 

227 (89.0)

392 (88.7)

 

 III/IV

78

28 (11.0)

22 (11.3)

19 (10.1)

9 (15.3)

 

28 (11.0)

50 (11.3)

 

IPI score

     

0.763

  

0.421

 0–1

597

222 (87.1)

164 (84.1)

162 (86.2)

49 (83.1)

 

222 (87.1)

375 (84.8)

 

 2–5

100

33 (12.9)

31 (15.9)

26 (13.8)

10 (16.9)

 

33 (12.9)

67 (15.2)

 

KPI score

     

0.974

  

0.984

 0–1

478

175 (68.6)

133 (68.2)

128 (68.1)

42 (71.2)

 

175 (68.6)

303 (68.6)

 

 2–4

219

80 (31.4)

62 (31.8)

60 (31.9)

17 (28.8)

 

80 (31.4)

139 (31.4)

 
  1. ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, LN lymph node, EBV Epstein–Barr virus, CRP C-reactive protein, IPI International Prognostic Index, KPI Korean Prognostic Index
  2. aData of EBV-DNA copy number were available for 171 patients, and the median value was 1530 copies/mL
  3. bData of serum CRP levels were available for 228 patients, and the CRP level >10 mg/L was used as the cutoff value